DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential
1 Main Capital, a boutique investment firm, recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Persistent Asset Partners Xin Huang | 2,613 | $18,396 | 0.01% | |
| 2. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 73,099 | $626,816.62 | 8,825,742 | 2025-11-25 | Filing | |
| $7.89 | 40,253 | $317,720.95 | 8,752,643 | 2025-11-24 | Filing | |
| $7.41 | 208,872 | $1,547,574.42 | 8,712,390 | 2025-11-21 | Filing | |
| $7.41 | 128,426 | $951,212.85 | 8,503,518 | 2025-11-20 | Filing | |
| $7.21 | 240,352 | $1,732,361.08 | 8,375,092 | 2025-11-19 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.24 | 2,855,847 | $3,526,971.05 | 0 | 2022-12-02 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,252,285 | $15,856,086 | 0% | |
| 2. | 894,115 | $6,296,035 | 0% | |
| 3. | 646,743 | $4,553,071 | 0% | |
| 4. | 382,317 | $2,691,512 | 0.48% | |
| 5. | 355,523 | $2,502,882 | 0% |